Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

from Merck Serono following the completion of two phase 2 clinical trials for adecatumumab. Total operating expenses were $13.1 million for the three months ended December 31, 2007, compared to $10.9 million for the same period in 2006. For the three months ended December 31, 2007, Micromet reported a net loss of $3.8 million, or $0.09 per basic and diluted share, compared to net income of $3.4 million, or $0.11 per basic and diluted share, for the same period in 2006. The positive net income in 2006 was due primarily to the milestone payment received from Merck Serono.

Year Ended December 31, 2007

Revenues for the year ended December 31, 2007 were $18.4 million, compared to $27.6 million for 2006. For the year ended December 31, 2007, Micromet reported operating expenses of $43.6 million, compared to $61.2 million for the same period in 2006. In connection with the merger with CancerVax, Micromet recorded a non-recurring, non-cash charge of $20.9 million in the second quarter of 2006 due to the immediate write-off of CancerVax's in- process research and development programs. For the year ended December 31, 2007, net loss was $20.1 million, or $0.55 per basic and diluted share, compared to $34.0 million, or $1.29 per basic and diluted share, for 2006.

Micromet's cash and cash equivalents were $27.1 million as of December 31, 2007. Net cash used in operating activities was $14.3 million for the year ended December 31, 2007 and $15.4 million in 2006. Based on the status of our development programs, management believes that the cash balance at December 31, 2007 is sufficient to fund operations into the second quarter of 2009.

2008 Outlook:

-- Micromet will present an update on its proprietary BiTE antibody

technology platform and new BiTE antibody programs at the conference of

the American Association of Cancer Research (AACR) in April 2008.

-- A phase 1/2 clinical trial evaluating MT103 in patients wi
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Research and Markets has ... Diagnostics Market (Product types, Application, Technology, End User ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation ... their offering. This new report ... users and Geography) Global Size, Industry Analysis, Trends, ...
(Date:10/22/2014)... October 22, 2014 Involution Studios ... release of a new infographic, Understanding Ebola . ... a beautifully designed, easy to follow informative tool for ... of outbreak, symptoms and prevention. , "As the news ... the 2014 Ebola outbreak represents not only a healthcare ...
(Date:10/22/2014)... According to new market research report ... Integration, Deployment & Support), by Service Model (SaaS, ... Others (Hybrid & Community)) - Global Forecast to ... Cloud Professional Services Market into various sub-segments with ... also identifies the drivers and restraints for this ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... June 29 The California Department of Labor today ... million grant to implement new workforce training programs for ... Initiative, a collaborative effort including CleanTECH San Diego, BIOCOM, San ... and the San Diego Workforce Partnership, captured the grant through ...
... SAN DIEGO , June 29 ... key commercialization milestones ahead of schedule. First, the company ... and commercial viability of a ,green, version of 1,4-butanediol ... confirmed the accelerated development time and reduced development and ...
... June 29, 2010 , , , ... it Will Carry the Disease and Therapy,Review: Impetigo Market Research Report in its Store. ... Browse the complete Report on:, http://www.reportsandreports.com/market-reports/disease-and-therapy-review-im ,petigo/ , ... The Impetigo Disease and Therapy Review provides an overview ...
Cached Biology Technology:San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry 2San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry 3San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry 4Genomatica Delivers Pilot-Scale Validation in Sustainable Chemical Manufacturing 2Genomatica Delivers Pilot-Scale Validation in Sustainable Chemical Manufacturing 3Genomatica Delivers Pilot-Scale Validation in Sustainable Chemical Manufacturing 4Disease and Therapy Review: Impetigo Now Available at ReportsandReports 2Disease and Therapy Review: Impetigo Now Available at ReportsandReports 3Disease and Therapy Review: Impetigo Now Available at ReportsandReports 4Disease and Therapy Review: Impetigo Now Available at ReportsandReports 5
(Date:10/25/2014)... --  MedNet Solutions , a global life sciences technology ... to announce the 2014 iMedNet User Group ... in Bloomington, Minnesota on October ... and promises to be informative, productive and enjoyable for ... meeting is iMedNet™ EDC , MedNet,s ...
(Date:10/25/2014)... This report covers the specifics of microRNA ... heavy pursuit of research due to its versatility and ... other RNA components. miRNA,s non-coding nature and ability to ... use as a biomarker for a variety of diseases. ... for the advancement in therapeutic development. Furthermore there are ...
(Date:10/25/2014)... -- A recent report, "Genetic Testing Market Outlook 2018", ... genetic testing market. A comprehensive introduction of gene-based tests, ... report. On account of our analysis of the past ... challenges; forecast for genetic testing has been drawn, according ... a CAGR of around 9% during 2013-2018. Our ...
Breaking Biology News(10 mins):MedNet Solutions To Host Third Annual iMedNet User Group Meeting 2MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Genetic Testing Market Outlook 2018 2
... Scientists at St. Jude Children's Research Hospital have announced ... against one antigenic variant of the avian influenza virus ... virus. Vaccines based on this model might therefore be ... epidemic) until a new vaccine could be developed specifically ...
... half of human cancers involve mutations in the p53 ... normal p53 protein in defending against cancer. Similarly, roughly ... occur in its DNA-binding core domain, pointing to this ... its anti-cancer activity. , Clearly, a detailed view of ...
... a lifetime of daily injections to replace the ... as a host of risks that includes blindness, ... particularly those afflicted with juvenile diabetes, transplants of ... might alleviate these problems. Unfortunately, there are not ...
Cached Biology News:Scientists to employ Arctic ice and polar bears to protect diversity of world's crops 2Structure determined for p53 tumor suppressor protein as bound to DNA for anti-cancer activity 2Successful transplantation from pig embryos to mice 2
... I can be used in intracellular staining ... cells and to serve as an antibody ... cell permeabilization is a reversible process, it ... the presence of saponin during intracellular staining. ...
... raised against a partial recombinant ... PPP4C (NP_002711, 218 a.a. ... protein with GST tag. ... NM_002720 Protein ...
... Eppendorf Thermomixer R offers maximum application ... shaking, heating, and cooling. Its active ... application and temperature control ranges. Five ... 24 micro test tubes, are available ...
Mouse monoclonal antibody raised against a partial recombinant PDE2A. NCBI Entrez Gene ID = PDE2A...
Biology Products: